IMI’s GNA NOW Consortium looking for novel antibiotic program to progress to IND
Interested candidates are asked to submit a non-confidential Expression of Interest (EoI), which will be evaluated by the GNA NOW Review Committee. The top three submissions will be asked to provide a full proposal.
- Expression of Interest submission: Friday 18 June 2021
- Programme proposal submission: Wednesday 25 August 2021
For more details on what the Consortium is looking for, what’s in it for interested candidates, and how to submit a proposal, please view the Open Call text.
Make sure to also register for the GNA NOW Open Call webinar on Wednesday 26 May, during which more details will be provided and time will be made for questions and answers.
For more information or to set up a one-on-one call with the project coordinators, please email the Consortium at: firstname.lastname@example.org
About GNA NOW
Established in July 2019, the GNA NOW Consortium is a European collaboration of 11 partners focused on progressing Gram-Negative antibiotics from lead optimization to the completion of Phase I trials. Working under the AMR Accelerator umbrella, the project is funded by the Innovative Medicines Initiative (IMI) with inkind contributions from industry partner, Evotec.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.